Albiflorin alleviates osteoporosis through suppression of osteoclast mitophagy via the Rap1a/ERK signaling pathway

Puntos clave

• Osteoporosis is alleviated by albiflorin via suppression of osteoclast mitophagy, providing promising insights for treatment.
• Mitophagy inhibition in osteoclasts leads to a noted decrease in bone resorption, enhancing bone integrity and strength.
• Analysis focused on the rap1a/erk signaling pathway, highlighting its role in regulating osteoclast function and health.
• These findings suggest that targeting the rap1a/erk pathway could lead to new osteoporosis treatments, but clinical trials are needed.